Ranibizumab News and Research

RSS

Darapladib shows promise in diabetic macular oedema

Placebo-controlled trial findings show that lipoprotein-associated phospholipase A2 inhibition modestly benefits the vision of patients with centre-involved diabetic macular oedema and warrants further investigation.

8 Jul 2015

ORT incidence increases in nAMD despite anti-VEGF treatment

Swiss researchers report that patients with neovascular age-related macular degeneration (nAMD) experience increased incidence of outer retinal tubulation over time, despite treatment with a vascular endothelial growth factor blocker.

30 Jun 2015

IQWiG examines added benefit of aflibercept in macular oedema after branch retinal vein occlusion

Since February 2015, aflibercept (trade name Eylea) has been available also for patients with impaired vision due to macular oedema that follows blockage of branch veins of the central retinal vein (branch retinal vein occlusion, BRVO).

24 Jun 2015

Study could offer new way to treat, prevent diabetes-associated blindness

Reporting on their study with lab-grown human cells, researchers at The Johns Hopkins University and the University of Maryland say that blocking a second blood vessel growth protein, along with one that is already well-known, could offer a new way to treat and prevent a blinding eye disease caused by diabetes.

26 May 2015

Anti-VEGF therapy benefits in wet AMD not sustained

Real-world experience of anti-vascular endothelial growth factor therapy for patients with wet age-related macular degeneration suggests that initial improvements in visual acuity are not maintained over time.

20 May 2015

No added benefit with pazopanib over ranibizumab for neovascular AMD

Pazopanib eye drops do not enhance visual outcomes in patients with neovascular age-related macular degeneration beyond those achieved with ranibizumab alone, study findings indicate.

19 May 2015

Similar diabetic macular oedema outcomes with deferred vs prompt laser therapy

Visual acuity outcomes are comparable in diabetic macular oedema patients who receive laser treatment 24 weeks or more after initiation of ranibizumab injections and those for whom laser therapy is initiated concurrently, show the 5-year results of a US study.

19 May 2015

Risk factors predict geographic atrophy after anti-VEGF treatment of RAP

Researchers have found three factors that could identify which patients with retinal angiomatous proliferation receiving anti-vascular endothelial growth factor treatment are likely to develop geographic atrophy.

19 May 2015

New edition of WHO Essential Medicines List includes new treatments for hepatitis C, cancers and multi-drug TB

WHO today published the new edition of its Model List of Essential Medicines which includes ground-breaking new treatments for hepatitis C, a variety of cancers (including breast cancer and leukaemia) and multi-drug resistant tuberculosis (TB), among others. The move opens the way to improve access to innovative medicines that show clear clinical benefits and could have enormous public health impact globally.

8 May 2015

WHO moves to improve access to lifesaving medicines for hepatitis C, Drug-resistant TB and cancers

The World Health Organization (WHO) today published the new edition of its Model List of Essential Medicines) which includes ground-breaking new treatments for hepatitis C, a variety of cancers (including breast cancer and leukaemia) and multi-drug resistant tuberculosis (TB), among others...

8 May 2015

Clinical study comparing effectiveness of three standard treatments for DME published in NEJM

Regeneron Pharmaceuticals, Inc. today announced that results from the National Institutes of Health-sponsored, Diabetic Retinopathy Clinical Research Network comparative effectiveness study in patients with Diabetic Macular Edema (Protocol T) were published in the New England Journal of Medicine and a corresponding slide set was posted online at DRCR.net.

20 Feb 2015

Ranibizumab drug reverses diabetes-related blindness

Ranibizumab, a prescription drug commonly used to treat age-related vision loss, also reverses vision loss caused by diabetes among Hispanic and non-Hispanic whites, according to a new study led by investigators from the University of Southern California Eye Institute.

19 Feb 2015

Retinal venular calibre predicts ranibizumab vision improvement

Retinal venular calibre may predict visual outcome in diabetic macular oedema patients given the anti-vascular endothelial growth factor monoclonal antibody ranibizumab, a pilot study suggests.

13 Feb 2015

Meta-analysis gives intravitreal ranibizumab vascular adverse risk profile

Intravitreal ranibizumab treatment for age-related macular degeneration does not elevate the risk of mortality, suggests a meta-analysis published in Ophthalmology.

13 Feb 2015

VEGF inhibition does not regulate collateral vessels in retinal vein occlusion

The formation of collateral vessels does not appear to improve visual acuity in patients with branch or central retinal vein occlusion, and is unaffected by anti-vascular endothelial growth factor therapy, a retrospective analysis suggests.

13 Feb 2015

Pfenex, Hospira sign agreement to develop and commercialize LUCENTIS biosimilar

Pfenex Inc., a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, and Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, today announced that the companies have entered into an agreement to exclusively develop and commercialize for worldwide sales PF582, Pfenex's biosimilar candidate to Genentech's LUCENTIS (ranibizumab injection).

10 Feb 2015

Study: Lower-income students in China have better vision compared to middle-class counterparts

In one of the largest population-based studies ever conducted on nearsightedness in children, researchers have discovered that lower-income students in China have better vision than their middle-class counterparts. Data show that nearsightedness, also called myopia, is twice as prevalent in the middle-income province of Shaanxi compared to the poorer neighboring province of Gansu.

5 Feb 2015

Added benefit of aflibercept not proven in patients with diabetic macular oedema

Since August 2014, aflibercept (trade name Eylea) has been available also for patients with visual impairment due to diabetic macular oedema (DMO). The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether this drug offers an added benefit over the appropriate comparator therapy.

15 Dec 2014

Apellis Pharmaceuticals completes $33M private placement of Series C Preferred Stock

Apellis Pharmaceuticals, Inc., a leading biotechnology company applying immunotherapy to autoimmune disease, today announced that it has completed a $33M private placement of its Series C Preferred Stock.

2 Dec 2014

Success for nurse practitioner-delivered intravitreal injection service for wAMD

Well-trained nurse practitioners can successfully provide an injection service for the treatment of wet age-related macular degeneration with ranibizumab, an audit shows.

1 Dec 2014

Ranibizumab News and Research

Darapladib shows promise in diabetic macular oedema

ORT incidence increases in nAMD despite anti-VEGF treatment

IQWiG examines added benefit of aflibercept in macular oedema after branch retinal vein occlusion

Study could offer new way to treat, prevent diabetes-associated blindness

Anti-VEGF therapy benefits in wet AMD not sustained

No added benefit with pazopanib over ranibizumab for neovascular AMD

Similar diabetic macular oedema outcomes with deferred vs prompt laser therapy

Risk factors predict geographic atrophy after anti-VEGF treatment of RAP

New edition of WHO Essential Medicines List includes new treatments for hepatitis C, cancers and multi-drug TB

WHO moves to improve access to lifesaving medicines for hepatitis C, Drug-resistant TB and cancers

Clinical study comparing effectiveness of three standard treatments for DME published in NEJM

Ranibizumab drug reverses diabetes-related blindness

Retinal venular calibre predicts ranibizumab vision improvement

Meta-analysis gives intravitreal ranibizumab vascular adverse risk profile

VEGF inhibition does not regulate collateral vessels in retinal vein occlusion

Pfenex, Hospira sign agreement to develop and commercialize LUCENTIS biosimilar

Study: Lower-income students in China have better vision compared to middle-class counterparts

Added benefit of aflibercept not proven in patients with diabetic macular oedema

Apellis Pharmaceuticals completes $33M private placement of Series C Preferred Stock

Success for nurse practitioner-delivered intravitreal injection service for wAMD

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News